Get ready for a powerhouse session of innovation and investor insight!
This Forum spotlights a hand-picked lineup of breakthrough start-ups delivering dynamic 10-minute presentations — including Q&A — designed to spark conversation, curiosity, and opportunity.
You’ll also get an exclusive look at how some of our past presenting companies are accelerating forward, as they share their newest wins, major milestones, and what’s coming next.
Fresh ideas. Real traction. High-impact connections.
It’s all happening here.
Auctus Surgical is solving scoliosis with a minimally invasive implant that preserves motion and grows with the child. These "braces" for the spine are designed to address the $10B worldwide deformity market with applications for children and adults. Management has 90 years combined in the industry and $1.75B in investor value creation from previous exits. They believe that children with scoliosis should not be limited and deserve the same active healthy life as their peers.
Elucidate Bio is a disruptive AI/Cell Biology startup that is already creating cancer breakthroughs. Validated by Pharma experts without requiring FDA approval, they have attractive revenues that bring them close to break-even at seed stage.
Northern Vascular has developed a light-activated gel and delivery system to treat neurovascular disorders, including aneurysms, tumours, and beyond. The gel is non-toxic, water soluble, and allows clinicians greater control over when, where, and how embolization occurs through exposure to light, with the potential to disrupt a $5.5B market.
Stingray’s Vizenpistat (SR-8541A) is an oral first in class best innate immune checkpoint inhibitor, badly needed to help adaptive immune checkpoint inhibitors in the ½ of all tumors where they do not work. In 2 clinical trials, Vizenpistat has shown greater efficacy and high safety in clinical trials than competition.
Ordaos Bio’s lab-in-the-loop AI platform designs novel biologics, validated by successful projects with top pharma. Their 5-day "lab-in-the-loop" cycle promises better drugs to patients faster and more reliably than alternatives. With $40M+ in near-term license potential, they are raising a $7M bridge to advance lead assets through in vivo studies.